NCT01846104已完成1 期
Safety and Immunogenicity of a Booster Dose (50 µg) of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Previously Vaccinated Healthy Adults
U.S. Army Medical Research and Development Command2 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2013年4月30日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Number of Vaccinated Participants Who Experienced Adverse Events by Nature and Severity.
研究概览
简要总结
The purpose of this study is to evaluate the safety and immunogenicity of a single 50-μg booster dose of RVEc. Subjects will be recruited from the cohort that received three 50-μg doses of RVEc in a Phase 1 trial (NCT01317667).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Study subjects must have received the 3 priming doses of RVEc at the 50-µg dosage.
- •Study subjects must be 18 years old at time of screening and no older than 50 years old at time of vaccination.
- •Subjects must weigh at least 110 pounds at time of screening.
- •Subjects must be in good health as judged from medical history, physical examination, EKG, hematology, clinical chemistries, urinalysis, hepatitis serology, and HIV antibody test (Table 4) and be medically cleared for participation by an investigator. If any HIV or hepatitis testing is positive, the individual will be provided with counseling and referral for health care.
- •Females of child-bearing potential must have a negative pregnancy test on screening and the morning of vaccination prior to receipt of the vaccine and must agree to use a highly effective method of birth control during the first 3 months following receipt of RVEc. A highly effective method of birth control is defined as one with a failure rate of less than 1% per year. Acceptable birth control methods that meet this criterion include hormonal implants and injectables (Norplant, Depo-Provera, Lunelle, and Etonogestrel), combined oral contraceptives, the intrauterine devices (IUDs) Copper T (380-A) or Mirena (Levonorgestrel Intrauterine System), female sterilization (tubal ligation), sexual abstinence, or a vasectomized partner.
- •Female subjects must also agree not to breastfeed until at least 3 months after receiving the RVEc.
- •Study subjects must read and sign an approved informed consent.
- •Study subjects must be willing to return for all follow-up visits.
- •Study subjects must agree to report any AE that may or may not be associated with administration of the investigational product through the 6-month follow-up/closeout visit.
- •Study subjects must agree to abstain from excessive exercise (more than the usual routine) and excessive alcohol consumption (exceeds more than 2 drinks for males or 1 drink for females daily or binge drinking) for the duration of study participation.
排除标准
- •Acute or chronic medical conditions or immunodeficiency from a medical condition or medical treatment, medications, or dietary supplements that, in the investigator's opinion, would impair the subject's ability to respond to vaccination. Use of corticosteroids, other than inhaled corticosteroids, will not be permitted.
- •Severe hypersensitivity to any vaccine (anaphylaxis, angioedema, bronchospasm, or laryngospasm).
- •History of asthma, chronic obstructive pulmonary disease, or other current/residual diseases of the lungs.
- •Clinically significant abnormal laboratory tests.
- •Current smoker.
- •Any known allergies to sodium succinate, Tween-20 (a detergent), aluminum hydroxide, or kanamycin.
- •Receipt of any vaccine or investigational product within 30 days before or after vaccination with RVEc.
- •Receipt of RVEc is contraindicated based on SIRVA checklist/screening, as determined by PI.
结局指标
主要结局
Number of Vaccinated Participants Who Experienced Adverse Events by Nature and Severity.
时间窗: Six months
次要结局
- Number of Subjects Who Developed Total ELISA IgG Titers (≥ 1:500)(Six months)
- Number of Subjects Who Developed TNA Anti-ricin Toxin-neutralizing Antibody Titers (≥ 1:50)(Six months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineMeningococcal InfectionsMeningococcal MeningitisMeningitisNCT02752906Sanofi Pasteur, a Sanofi Company810
已完成
2 期
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)Acellular PertussisHaemophilus Influenzae Type bPoliomyelitisHepatitis BTetanusDiphtheriaNCT01453998GlaxoSmithKline657
已完成
3 期
Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014Infections, MeningococcalNCT00614614GlaxoSmithKline1,558
已完成
2 期
Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young AdultsInfections, StreptococcalNCT00896064GlaxoSmithKline43
已完成
3 期
Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old SubjectsNeisseria MeningitidisHaemophilus Influenzae Type bNCT00323050GlaxoSmithKline468